4.7 Article

Ciprofloxacin-Loaded Gold Nanoparticles against Antimicrobial Resistance: An In Vivo Assessment

Journal

NANOMATERIALS
Volume 11, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/nano11113152

Keywords

drug delivery; antibiotics; antimicrobial resistance; gold nanoparticles; ciprofloxacin; Enterococcus faecalis; liver and kidney infections; nanotechnology

Funding

  1. National Research Program for Universities (NRPU), Higher Education Commission (HEC), Pakistan [6035]

Ask authors/readers for more resources

Ciprofloxacin-loaded gold nanoparticles showed enhanced antibacterial activity against Enterococcus faecalis in mice, effectively eradicating the bacteria without causing hemolysis. They present a promising and biocompatible alternative therapeutic for infections resistant to conventional drugs. Further research is warranted.
Metallic nanoparticles, such as gold nanoparticles (AuNPs), have been extensively studied as drug delivery systems for various therapeutic applications. However, drug-loaded-AuNPs have been rarely explored in vivo for their effect on bacteria residing inside tissues. Ciprofloxacin (CIP) is a second-generation fluoroquinolone with a broad-spectrum of antibiotic properties devoid of developing bacteria resistance. This research is focused on the synthesis and physical characterization of Ciprofloxacin-loaded gold nanoparticles (CIP-AuNPs) and their effect on the colonization of Enterococcus faecalis in the liver and kidneys of mice. The successfully prepared CIP-AuNPs were stable and exerted enhanced in vitro antibacterial activity against E. faecalis compared with free CIP. The optimized CIP-AuNPs were administered (500 mu g/Kg) once a day via tail vein to infected mice for eight days and were found to be effective in eradicating E. faecalis from the host tissues. Moreover, unlike CIP, CIP-AuNPs were non-hemolytic. In summary, this study demonstrated that CIP-AuNPs are promising and biocompatible alternative therapeutics for E.-faecalis-induced infections resistant to conventional drugs (e.g., beta-lactams and vancomycin) and should be further investigated.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available